MEC Basic Full List ViewBy pinki@katapult.biz / February 16, 2025 MEC Basic Speciality — Amyotrophic Lateral Sclerosis (ALS) Biomarkers Biosimilars Bladder Blood Bone Brain Breast Cancer Central Nervous System (CNS) Clinical Trials Colon Colorectal Diversity, Equity & Inclusion Featured Content Gastrointestinal Genitourinary Genomic Geriatric Gynecology Head and Neck Hematologic Hematologic Maglinencies Hematology Immunotherapy Interventional Radiology Kidney Leukemia Liquid Biopsy Liver Lung Lymphoma Malignant Malignencies Melanoma Myelodysplastic Syndrome Myeloma Neuroendocrine Novel Oral & Maxillofacial Surgery Oral Cancer Ovarian Pancreas Pancreatic Pharmacological Prostate Radiation Radiology Renal Sarcoma Skin Solid Tumor Supportive & Palliative Care Survivorship Telemedicine Thoracic Thrombosis Thymic Thyroid Urothelial Author / Speaker Title Type of Media — Video Document Audio Events — 2024 California Cancer Consortium Conference (CCC) 2024 MCM 2024 MCM 2024 MLS Cleveland 2024 MLS Nashville 2024 MLS New Orleans 2024 MLS Seattle 2024 New Orleans Summer Cancer Meeting (NOSCM) 2024 PRIMO 2024 SPS Puerto Rico 2024 SPS Seattle 2024 SPECTRUM 2024 Sylvester APP Oncology Symposium 2024 WCS 2024 MaTOS Lungs 2025 PRIMO Search Everything « 1 … 44 45 46 47 48 … 62 » Management of Immunotherapy Related Adverse Events in Solid Tumors Alga S. Ramos Morales, PharmD, MS, BCPS, BCOP View PDF New Agents and New Toxicities in Malignant Hematology: BCL2 Inhibitors, Anti-BCMA, and FLT3 Inhibitors Nicole Ianniello, PharmD View PDF Front Line Metastatic NSCLC Pedro G. Solivan, MD View PDF Checkpoint Inhibition in GI Tumors with MSI-H & MMR Ahmed Zakari, MD View PDF Bladder and Kidney Cancers Pedro Barata, MD View PDF Melanoma: Metastatic and Adjuvant Therapy Sanjiv Agarwala, MD View PDF Overview of Gastric and Colon Cancers Ahmed Zakari, MD View PDF Prostate Cancer (no IO): Hormonal, PARP Inhibitors and Other. Ulka Vaishampayan, MD View PDF Targeted Therapy for Ginecology Oncology Malignancies Thomas Herzog, MD View PDF SCLC & Squamous NSCLC: New Standards Genelis Domingo, MD View PDF NTRK, Exon 20 insertions, and Potential Novel Pathways in NSCLC Luis E. Raez, MD, FACP, FCCP View PDF RET, MET, and BRAF Mutant Lung Cancer Tumors Edgardo S. Santos Castillero, MD, FACP View PDF EGFR & ALK Inhibitors for Mutated Lung Cancer Tumors Pedro G. Solivan, MD View PDF Controversial Management in Breast Cancer Mohammad Jahanzeb, MD, FACP, FASCO View PDF Breast Cancer Immunotherapy Mariana Chavez-MacGregor, MD View PDF Use of CDK4/6 and PIK3CA Inhibitors in Breast Cancer Noridza Rivera-Rodriguez, MD View PDF HER-2 Disease: Neoadjuvant and Adjuvant Therapy Luis Baez Vallecillo, MD View PDF ER/PR+ Metastatic Breast Cancer Vicente Valero, MD View PDF Challenges in End of Life Care Amber Thomassen, MA, MSN, APRN-BC, AOCNP View PDF Supportive Care in Oncology: What’s New in Treating Anemia, Neutropenia, Emesis and Bone Metastases Mildred Flores, RN, PhD View PDF Management of Common Toxicities Encountered With Checkpoint Inhibitors Rosanna Rodriguez, PA-C View PDF Biosimilars as Front Line Options for Cancer Care Jorge J. García, PharmD, MS, MHA, MBA, FACHE View PDF Mesothelioma and Thymoma – Limited and Advanced Stage Matthew Gubens, MD View PDF Small Cell Lung Cancer Millie Das, MD View PDF Other Immunotherapy Targets & Agents- Advanced NSCLC Jonathan W. Riess, MD, MS View PDF PD-1/PD-L1 Directed Immunotherapy for Advanced NSCLC Karen Kelly, MD View PDF Other Oncogene-Driven Cancers Collin Blakely, MD, PhD View PDF EGFR Mutated Lung Cancer - Advanced Stage David Gandara, MD View PDF ALK, ROS1, and BRAF Positive Lung Cancer Joel Neal, MD, PhD View PDF Tumor Biology, Pathology, Novel Diagnostics Tianhong “Tina” Li, MD, PhD View PDF
